Jiangsu Hengrui Medicine Co., Ltd. (SHA:600276)

Market Cap	473.23B
Revenue (ttm)	30.15B
Net Income (ttm)	7.35B
Shares Out	6.63B
EPS (ttm)	1.16
PE Ratio	61.26
Forward PE	49.91
Dividend	0.20 (0.28%)
Ex-Dividend Date	May 23, 2025

Volume	76,767,009
Average Volume	81,441,775
Open	72.17
Previous Close	72.31
Day's Range	70.48 - 74.04
52-Week Range	42.24 - 74.04
Beta	0.39
RSI	64.02
Earnings Date	Aug 21, 2025

About Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes drugs in China and internationally. The company develops antineoplastic drugs; surgery medications; medicines for oncology, autoimmune diseases, pain management, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory system diseases, hematological diseases, neurological diseases, and ophthalmology, etc.; analgesia and anesthesia products; and contrast agents. It is also involved in technical consulting; tra...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1970
• Employees: 20,238
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600276

Financial Performance

In 2024, Jiangsu Hengrui Medicine's revenue was 27.98 billion, an increase of 22.63% compared to the previous year's 22.82 billion. Earnings were 6.34 billion, an increase of 47.28%.